Literature DB >> 12161989

Long-term follow-up of central serous chorioretinopathy (CSCR).

M L Kanyange1, J J De Laey.   

Abstract

We studied retrospectively the clinical files of 6 patients (11 eyes), who were diagnosed as CSCR between 1968 and 1986. They were all males, aged from 28 tot 46. The initial diagnosis of CSCR was based on the clinical symptoms and ophthalmic findings. It was supported by fluorescein angiography and later also by ICG angiography. Eight eyes have been treated by laser. After a follow-up of at least 15 years: 2 of the treated eyes and one untreated eye developed subretinal neovascularization; 6 of the treated eyes and one untreated eye progressed to diffuse pigment epitheliopathy; Final visual acuity was less than 2/10 in 6 eyes.

Entities:  

Mesh:

Year:  2002        PMID: 12161989

Source DB:  PubMed          Journal:  Bull Soc Belge Ophtalmol        ISSN: 0081-0746


  4 in total

1.  Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.

Authors:  Yoko Nomura; Ryo Obata; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2012-04-20       Impact factor: 2.447

2.  Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.

Authors:  Myrte B Breukink; Susan M Downes; Giuseppe Querques; Elon H C van Dijk; Anneke I den Hollander; Rocio Blanco-Garavito; Jan E E Keunen; Eric H Souied; Robert E MacLaren; Carel B Hoyng; Sascha Fauser; Camiel J F Boon
Journal:  Trials       Date:  2015-09-21       Impact factor: 2.279

3.  Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.

Authors:  Sang-Uk Park; Seung-Jun Lee; Moosang Kim
Journal:  Korean J Ophthalmol       Date:  2014-07-22

4.  Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy.

Authors:  Cihan Ünlü; Gurkan Erdogan; Tugba Aydogan; Betul Ilkay Sezgin Akcay; Esra Kardes; Gulunay Akcali Kiray; Tahir Kansu Bozkurt
Journal:  J Ophthalmic Vis Res       Date:  2016 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.